Medical Aspects of Chemical Warfare (2008) - The Black Vault

Medical Aspects of Chemical Warfareproperties of, 292published analytical approaches for the analysis of CVAA inurine (figure), 729putative mechanism by which lewisite causes tissue damage(figure), 292sample preparation methods for gas chromatographic/massspectrometric analysis of CVAA (exhibit), 730toxicity, 292treatment, 293, 667US production of, 117Veterans Administration study on the effects of mustard agentand lewisite exposure, 312–313Ley, Robertviews on chemical warfare, 49LHON. See Leber hereditary optic neuropathyLibyaincrease in chemical weapon development, 65use of chemical weapons against Chad, 63Lidocainesaxitoxin treatment, 627tetrodotoxin treatment, 627Limitation of Arms Conferencestockpiling of chemical weapons and, 44Lindsay, C.D.mustard agent injury treatment, 285Liquid chromatographyblood sample analysis for mustard agent, 723, 725, 726combined with gas chromatography for mustard agent assays,711, 713combined with mass spectrometry for mustard agent assays,692, 713, 720–721, 723nerve agent assays and, 695phosgene, 737urine sample analysis for mustard agent, 716–717, 718, 720–721“Little John” rocketsnerve agent delivery, 122Livens projectorsdescription, 118, 119Long-term health effectschloropicrin exposure, 457cyanide poisoning, 387–389dibenz[b,f]-1,4-oxazepine exposure, 468–469lewisite exposure, 294mustard agent exposure, 291, 312–316nerve agent exposure, 177–179oleoresin capsicum exposure, 4551-chloroacetophenone exposure, 463–464retrospective studies and, 313toxic industrial chemical exposure, 354–355, 3652-chlorobenzylidene malononitrile exposure, 452Loos, Battle ofchlorine gas attacks, 18–19Lorazepambrevetoxin intoxication treatment, 630LSD intoxication treatment, 417nerve agent exposure treatment, 190, 223Lott, Josephchemical warfare proposal, 12LRN. See Laboratory Response NetworkLSD. See Lysergic acid diethylamideLudendorff, Gen. ErichLys Defensive and, 26Lund,burn severity assessment, 282Lundy, P.M.VX nerve agent research, 529Lung cancermustard agent exposure and, 313–314Lungs. See Pulmonary systemLuten, Dr. RobertBroselow-Luten system and, 681–683Chemical Warfare Involving Kids Response Project and, 681Lys defensivechemical attacks, 26–27Lysergic acid diethylamideblood level assays, 417Chemical Corps testing of, 416–417historical background of research on, 413–414mode of action, 417physiological effects, 417, 428research on effects of, 56toxicity of, 417treatment for intoxication by, 417unique features of, 416unpredictability of effects, 417–418MM22 automatic chemical agent detector and alarmdescription, 544description and uses, 577M272 chemical agent water testing kitsdescription and detection limits, 577M45 chemical-biological masksdescription, 566Land Warrior program and, 567voicemitters, 566–567M53 chemical-biological protective masksaudio frequency modifiers, 569protective hoods, 568–569sizes, 568US Special Operations Command requirements, 568M8 chemical detector paperdescription and uses, 544, 575M9 chemical detector paperdescription and uses, 544, 575–576M28 collective protection equipmentdescription and uses, 585M295 equipment decontamination kitsdescription and uses, 582M17 lightweight decontamination systemdescription and uses, 583M41 protection assessment test systemdescription, 564fit and, 563M21 remote sensing chemical agent alarmsdescription, 578placement of, 579uses of, 579M20 simplified collective protection equipmentdescription, 586IPE and, 586M291 skin decontamination kitsAmbergard resin and, 652–653components, 536, 581description, 533, 581introduction of, 536Reactive Skin Decontamination Lotion and, 536, 653SERPACWA and, 652M100 sorbent decontamination systemdescription and uses, 582–583M256A1 chemical agent detector kitsdescription and uses, 576–577detection limits, 577M42A2 chemical-biological combat vehicle masksxlvi